New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia

Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news